StockData
Alaunos Therapeutics, Inc. logo

Alaunos Therapeutics, Inc. (TCRT) stock

TCRTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 4/30
$1.72+0.06 (+3.61%)

Close on Nov 18, 2026Market cap $4.37MP/E –Yield –

Alaunos Therapeutics cash

Cash and short-term investments held at the end of each period.

Alaunos Therapeutics's cash was $124.00K at Jun 30, 2026. For fiscal 2025 it was $1.39M, up 26.9% from the year before. Over ten years it grew -37.0% a year on average. The highest annual figure on record is $140.72M in fiscal 2015.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.39M+26.9%
FY2024Dec 31, 2024$1.09M-82.0%
FY2023Dec 31, 2023$6.06M-88.6%
FY2022Dec 31, 2022$53.00M-30.3%
FY2021Dec 31, 2021$76.05M-33.9%
FY2020Dec 31, 2020$115.07M+44.3%
FY2019Dec 31, 2019$79.74M+29.2%
FY2018Dec 31, 2018$61.73M-13.5%
FY2017Dec 31, 2017$71.33M-12.4%
FY2016Dec 31, 2016$81.44M-42.1%
FY2015Dec 31, 2015$140.72M+228.8%
FY2014Dec 31, 2014$42.80M-37.2%
FY2013Dec 31, 2013$68.20M-7.0%
FY2012Dec 31, 2012$73.31M-30.0%
FY2011Dec 31, 2011$104.71M+73.4%
FY2010Dec 31, 2010$60.39M+23.7%
FY2009Dec 31, 2009$48.84M+329.2%
FY2008Dec 31, 2008$11.38M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$124.00K-95.7%
Q1 FY2026Mar 31, 2026$354.00K+11.0%
Q4 FY2025Dec 31, 2025$1.39M+26.9%
Q3 FY2025Sep 30, 2025$1.94M+15.2%
Q2 FY2025Jun 30, 2025$2.88M+16.8%
Q1 FY2025Mar 31, 2025$319.00K-92.3%
Q4 FY2024Dec 31, 2024$1.09M-82.0%
Q3 FY2024Sep 30, 2024$1.68M-85.9%
Q2 FY2024Jun 30, 2024$2.46M-86.5%
Q1 FY2024Mar 31, 2024$4.15M-88.9%
Q4 FY2023Dec 31, 2023$6.06M-88.6%
Q3 FY2023Sep 30, 2023$11.94M-76.9%
Q2 FY2023Jun 30, 2023$18.32M-69.5%
Q1 FY2023Mar 31, 2023$37.43M-45.2%
Q4 FY2022Dec 31, 2022$53.00M-30.3%
Q3 FY2022Sep 30, 2022$51.75M-43.6%
Q2 FY2022Jun 30, 2022$60.01M-21.8%
Q1 FY2022Mar 31, 2022$68.26M-40.7%
Q4 FY2021Dec 31, 2021$76.05M-43.9%
Q3 FY2021Sep 30, 2021$91.73M-40.3%
Q1 FY2021Jun 30, 2021$76.75M-55.1%
Q4 FY2020Dec 31, 2020$115.07M+44.3%
Q3 FY2020Sep 30, 2020$135.47M+53.2%
Q2 FY2020Jun 30, 2020$153.52M+252.4%
Q1 FY2020Mar 31, 2020$171.00M+232.1%
Q4 FY2019Dec 31, 2019$79.74M+29.2%
Q3 FY2019Sep 30, 2019$88.42M+175.3%
Q2 FY2019Jun 30, 2019$43.56M+6.8%
Q1 FY2019Mar 31, 2019$51.49M+0.7%
Q4 FY2018Dec 31, 2018$61.73M-13.5%
Q3 FY2018Sep 30, 2018$32.12M-61.9%
Q2 FY2018Jun 30, 2018$40.79M-58.0%
Q1 FY2018Mar 31, 2018$51.11M-23.1%
Q4 FY2017Dec 31, 2017$71.33M-12.4%
Q3 FY2017Sep 30, 2017$84.41M-10.9%
Q2 FY2017Jun 30, 2017$97.19M-10.8%
Q1 FY2017Mar 31, 2017$66.45M–
Q4 FY2016Dec 31, 2016$81.44M–
Q3 FY2016Sep 30, 2016$94.68M–
Q2 FY2016Jun 30, 2016$109.00M–

More Alaunos Therapeutics figures

See a number that looks wrong?